[ad_1]
NEW YORK – (BUSINESS WIRE) – July 10, 2018 – Today, Celmatix, the next-generation women's health care company, has announced the launch of MyFertility Compass ™, an online tool that helps women to understand their personal likelihood of having a baby, with or without the use of common fertility treatments, including in vitro fertilization. MyFertility Compass harnesses world-class science to educate women about factors that could affect their fertility while providing data-driven projections to help women better associate with their doctors for family travel. "19659002 do not talk to their doctors when they are on their family building trips and instead of consulting the internet.Our mission has always been to help women be more proactive about their fertility and their health through a better science and better customization, "said Dr. Piraye Yurttas Beim, founder and CEO of Celmatix." It has been extremely gratifying to see how our Polaris® platform has influenced more than 90,000 patients in fertility centers. and how our Fertilome® genetic test brings a real personalized medicine to reproductive health.These two products are currently mainly accessible by medical specialists, so we wanted to build a tool that would impact more women, earlier in their travels. "
MyFertility Compass is free and easy to use. When a woman who is currently trying to become pregnant visits www.myfertilitycompass.io, she will be asked to provide her age and answer questions about her lifestyle and her health that may impact her fertility. Using this information, MyFertility Compass generates a custom fertility report. For women under age 35 who have been trying for more than a year, and women over 35 who have been trying for at least six months, their personalized report will also include their probabilities of success under the supervision of a basic or more advanced physician.
The models that feed MyFertility Compass are based on a combination of peer-reviewed scientific studies and Celmatix's proprietary predictive models, which were developed from a set of closely-structured, fact-based data. Million results of fertility treatments. 19659002] "As an Obstetrician Gynecologist and Fertility Specialist, I know that often women who travel with family worry too early or too often," says Linda C. Giudice, MD, Ph.D., Distinguished Professor and Robert B. Jaffe MD Full Professor in Reproductive Sciences at the Department of Obstetrics, Gynecology and Reproductive Sciences of the University of California at San Francisco (UCSF), as well as a member Celmatix Scientific Advisory Board. "MyFertility Compass is an innovative and valuable resource that allows women to assess their fertility potential and their pathways to optimize the achievement of their family building goals." Data-driven tools such as MyFertility Compass may have important impact by providing women with more personalized and relevant perspectives.With the demographic trends of women expecting later in life to start or expand their families, directing women to the right care at the right time is more important than ever . "
To learn more about your fertility journey, visit www.myfertilitycompass .io. For more information on Celmatix, visit www.celmatix.com
About Celmatix Inc.
Celmatix is a next-generation women's health business that transforms reproductive health care through genomics and Big Data. Founded in 2009 and based in New York, Celmatix disrupts the way women approach their fertility journey throughout their lives by giving them and their doctors more personalized information. The company's research-based products include the Fertilome® test, the first multigene panel test in the world that reveals what a woman's DNA says about her reproductive health, Polaris®, a platform for Predictive real-time analysis used in major fertility clinics in the United States. that helps physicians optimize patient outcomes and improve patient experience, and MyFertility Compass ™, a data-driven education tool that gives women who are currently trying to design their fertility potential .
See the source version on businesswire.com:https: //www.businesswire.com/news/home/20180710005189/en/
CONTACT: Media
Celmatix Inc.
Margaret Farrell
(203) 434-2240
KEYWORD: UNITED STATES NORTH AMERICA NEW YORK
KEY WORD: WOMEN TECHNOLOGY INTERNET GENETIC HEALTH BABY / CONSUMER MATERNITY GENERAL HEALTH [19659002] SOURCE: Celmatix Inc.
Copyright Business Wire 2018. [19659002] PUB: 07/10/2018 09:00 / DISC: 07/10/2018 09:01 AM
http: //www.businesswire .com / news / home / 20180710005189 / en
Copyright Business Wire 2018.
[ad_2]
Source link
